Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
Transcriptional control of gene expression is fundamental to all cellular processes. Conversely, transcriptional dysregulation is a hallmark of cancer. While this hallmark is a key driver of all malignancy-related process, it also represents a vulnerability that can be exploited therapeutically. Pro...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325001093 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850188621650329600 |
|---|---|
| author | Razia Rahman Luke A. Selth |
| author_facet | Razia Rahman Luke A. Selth |
| author_sort | Razia Rahman |
| collection | DOAJ |
| description | Transcriptional control of gene expression is fundamental to all cellular processes. Conversely, transcriptional dysregulation is a hallmark of cancer. While this hallmark is a key driver of all malignancy-related process, it also represents a vulnerability that can be exploited therapeutically. Prostate cancer is a prime example of this phenomenon: it is characterised by aberrant transcription and treated with drugs that influence transcriptional pathways. Indeed, the primary oncogenic driver and therapeutic target of prostate cancer, the androgen receptor (AR), is a transcription factor. Moreover, a plethora of other transcriptional regulators, including transcriptional cyclin-dependent kinases (CDK7, CDK8 and CDK9), MYC and Bromodomain-containing protein 4 (BRD4), play prominent roles in disease progression. In this review, we focus on the roles of transcriptional CDKs in prostate cancer growth, metastasis and therapy resistance and discuss their interplay with AR, MYC and BRD4. Additionally, we explore recent advances in the therapeutic targeting of transcriptional CDKs and propose how these strategies could be effectively harnessed for the treatment of prostate cancer. |
| format | Article |
| id | doaj-art-90096ec9217a4328a2da2eff145d069e |
| institution | OA Journals |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-90096ec9217a4328a2da2eff145d069e2025-08-20T02:15:51ZengElsevierTranslational Oncology1936-52332025-05-015510237810.1016/j.tranon.2025.102378Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancerRazia Rahman0Luke A. Selth1Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South AustraliaFlinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia; Flinders University, Freemasons Centre for Male Health and Wellbeing, Adelaide, South Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia; Corresponding author at: Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia.Transcriptional control of gene expression is fundamental to all cellular processes. Conversely, transcriptional dysregulation is a hallmark of cancer. While this hallmark is a key driver of all malignancy-related process, it also represents a vulnerability that can be exploited therapeutically. Prostate cancer is a prime example of this phenomenon: it is characterised by aberrant transcription and treated with drugs that influence transcriptional pathways. Indeed, the primary oncogenic driver and therapeutic target of prostate cancer, the androgen receptor (AR), is a transcription factor. Moreover, a plethora of other transcriptional regulators, including transcriptional cyclin-dependent kinases (CDK7, CDK8 and CDK9), MYC and Bromodomain-containing protein 4 (BRD4), play prominent roles in disease progression. In this review, we focus on the roles of transcriptional CDKs in prostate cancer growth, metastasis and therapy resistance and discuss their interplay with AR, MYC and BRD4. Additionally, we explore recent advances in the therapeutic targeting of transcriptional CDKs and propose how these strategies could be effectively harnessed for the treatment of prostate cancer.http://www.sciencedirect.com/science/article/pii/S1936523325001093Prostate cancerCyclin-dependent kinaseAndrogen receptorTargeted therapiesTranscription |
| spellingShingle | Razia Rahman Luke A. Selth Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer Translational Oncology Prostate cancer Cyclin-dependent kinase Androgen receptor Targeted therapies Transcription |
| title | Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer |
| title_full | Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer |
| title_fullStr | Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer |
| title_full_unstemmed | Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer |
| title_short | Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer |
| title_sort | cyclin dependent kinases as mediators of aberrant transcription in prostate cancer |
| topic | Prostate cancer Cyclin-dependent kinase Androgen receptor Targeted therapies Transcription |
| url | http://www.sciencedirect.com/science/article/pii/S1936523325001093 |
| work_keys_str_mv | AT raziarahman cyclindependentkinasesasmediatorsofaberranttranscriptioninprostatecancer AT lukeaselth cyclindependentkinasesasmediatorsofaberranttranscriptioninprostatecancer |